Breaking News

Covis Acquires Rights to Sanofi Drugs

April 5, 2013

Will promote five products in the U.S.

Covis Pharma Sarl has entered an agreement with sanofi-aventis U.S. and its affiliates to acquire full commercial rights to Nilandron, Plaquenil, Rilutek, Uroxatral, and Kayexalate in the U.S. The products are for prostate cancer, anti-malarial, ALS, Benign Prostatic Hyperplasia (BPH), and dangerously high levels of potassium in the blood, respectively. Together these products had sales of $114.6 million in the U.S. in 2012. Sanofi will retain the existing rights for these products outside the U.S.
 
Covis Pharma will promote these products through its U.S. distributor, Covis Pharmaceuticals, Inc. Sanofi will manufacture and supply the products for Covis Pharma.
 
"We are very pleased to announce the addition of these products to our existing portfolio," said Jack Davis, chief executive officer of Covis Pharma. "Covis will continue to supply consistent, top quality, branded pharmaceuticals, ensuring that patients receive the therapeutic care they need."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks